To access all features of this site, you must enable Javascript. Here are the instructions for enabling Javascript in your web browser.
To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
News
Researchers from the SPI (DMTS) and the Women & Infants Hospital in Providence have laid the molecular basis for the neuroprotection of a purine derivative in a preclinical model of neonatal hypoxic-ischemic encephalopathy (HIE). The promising results support the development of this drug candidate to treat HIE in neonates.
A team from I2BC, in collaboration with the NIMBE (CEA-Iramis), is unveiling the nature of the interactions of human alpha-synuclein (hαSn) with polyethylene nanoplastics, using molecular dynamics simulations and experimental methods.
Researchers from SPI (DMTS) propose immunodiagnostic and immunotherapeutic approaches based on the use of innovative antibodies targeting two subtypes of endothelin receptors (ETA and ETB), recognised as relevant therapeutic targets in oncology.
The COVID-PATH project was officially launched on March 12, 2025, to investigate the gastrointestinal impact of SARS-CoV-2 and its link to Long COVID.
As a stakeholder in the NOMATEN Centre of Excellence for innovative multifunctional materials, the CEA-Joliot Institute supports its development by regularly organizing training sessions for its staff. The latest examples.
Top page
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.